" Chemotherapy-resistant lung cancer – ‘Tribetarna®’: Benitec’s lung cancer program targeting the gene responsible for chemotherapy resistance, beta III tubulin (TUBB3), continues to make encouraging progress toward the clinic. Significant milestones include:
o Continuing the development of Tribetarna® undertaking additional tox, biodistribution and efficacy studies requested by the FDA, and to optimise dosing and treatment regimes to enable maximal knockdown of the target gene, TUBB3, in the clinical setting
o Advancing the development of a Companion Diagnostic enabling identification of patients likely to benefit from treatment and correlation of efficacy with TUBB3 patient levels
o Professor Maria Kavallaris from UNSW published research identifying additional tumours that may benefit from treatment with Tribetarna®. These tumours include renal and pancreatic cancer."
Half yearly update would indicate 2016 IMO. Not IND ready yet and remember how much work the IND was.
BLT Price at posting:
78.5¢ Sentiment: None Disclosure: Held
